Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01045096
First received: January 7, 2010
Last updated: March 8, 2012
Last verified: March 2012
Results First Received: January 30, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Parallel Assignment;   Masking: Open Label
Condition: Gastroesophageal Reflux
Intervention: Drug: Dexlansoprazole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants took part in this study at 3 investigative sites in the United States from 04 March 2010 to 09 February 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
36 participants with gastroesophageal reflux disease were assigned to 1 of 3 once daily (QD) treatment regimens (15 mg, 30 mg or 60 mg dexlansoprazole) based on baseline body weight.

Reporting Groups
  Description
Dexlansoprazole 15 mg QD Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
Dexlansoprazole 30 mg QD Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
Dexlansoprazole 60 mg QD Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days

Participant Flow:   Overall Study
    Dexlansoprazole 15 mg QD     Dexlansoprazole 30 mg QD     Dexlansoprazole 60 mg QD  
STARTED     12     12     12  
Pharmacokinetic Set     9 [1]   11     11  
COMPLETED     9     12     12  
NOT COMPLETED     3     0     0  
Withdrawal by Subject                 2                 0                 0  
Other                 1                 0                 0  
[1] All patients with at least one estimable PK parameter for dexlansoprazole on Day 7.



  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to Reach the Peak Plasma Concentration (Tmax)   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

2.  Primary:   The Peak Plasma Concentration (Cmax)   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

3.  Primary:   Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc))   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

4.  Primary:   Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24))   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

5.  Other Pre-specified:   Dose-normalized Peak Plasma Concentration (Cmax/Dose)   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

6.  Other Pre-specified:   Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc)/Dose)   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]

7.  Other Pre-specified:   Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24)/Dose)   [ Time Frame: Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules. ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Sr. VP, Clinical Science
Organization: Takeda Global Research and Development Center, Inc.
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com


No publications provided


Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01045096     History of Changes
Other Study ID Numbers: T-P107-174, U1111-1112-1684
Study First Received: January 7, 2010
Results First Received: January 30, 2012
Last Updated: March 8, 2012
Health Authority: United States: Food and Drug Administration